Two Hot Company’s Looking To Save Lives On Two Different Standards: PWRM, PIP

Power3 Medical Products, Inc. (OTCBB: PWRM)

Stem Cells have the remarkable potential to develop into many different cell types during early life and growth. In addition, in many tissues they serve as an internal repair system, dividing essentially without limit to replenish other cells.

When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

The latter is where Alzheimer’s research comes into play.

Stage I clinical trials are about to begin using Adult Stem Cells to hopefully cure Alzheimer’s disease.

The first phase of a clinical development program is designed to assess safety, determine a dose range and identify potential side effects

Using (OTCBB: PWRM)’s Biomarkers to identify Alzheimer’s, allows the early stage detection, and early detection means more options.

(OTCBB: PWRM), is right in the fold of this potential cure, as their protein biomarker will allow for the earliest detection.

Early detection is very relevant to cure. And (OTCBB: PWRM) is in the forefront of this fight.

We have (OTCBB: PWRM) on our radar it should also be on yours.

PharmAthene, Inc. (NYSE Amex: PIP)

(NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, has recently annoucned that the Company will present at the Noble Financial Sixth Annual Equity Conference ‘ONTRACK 2010′ on Monday, June 7, 2010 at 4:00 p.m. ET in Room 3 – Piquet. The Company’s presentation will be available via webcast under the Investor Relations section at the Company’s website at: www.PharmAthene.com.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene’

s lead product development programs include:

* SparVax™ – a second generation recombinant protective antigen (rPA) anthrax vaccine
* Third generation rPA anthrax vaccine
* Valortim® – a fully human monoclonal antibody for the prevention and treatment of anthrax infection
* Protexia® – a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit www.PharmAthene.com.